PE20221910A1 - Derivados de pirazolilo utiles como agentes anticancerigenos - Google Patents

Derivados de pirazolilo utiles como agentes anticancerigenos

Info

Publication number
PE20221910A1
PE20221910A1 PE2022001123A PE2022001123A PE20221910A1 PE 20221910 A1 PE20221910 A1 PE 20221910A1 PE 2022001123 A PE2022001123 A PE 2022001123A PE 2022001123 A PE2022001123 A PE 2022001123A PE 20221910 A1 PE20221910 A1 PE 20221910A1
Authority
PE
Peru
Prior art keywords
compound
anticancer agents
derivatives useful
atropisomer
optionally substituted
Prior art date
Application number
PE2022001123A
Other languages
English (en)
Inventor
Simona Cotesta
Marc Gerspacher
Catherine Leblanc
Edwige Liliane Jeanne Lorthiois
Bo Liu
Rainer Machauer
Robert Mah
Christophe Mura
Pascal Rigollier
Nadine Schneider
Stefan Stutz
Andrea Vaupel
Nicolas Warin
Rainer Wilcken
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20221910A1 publication Critical patent/PE20221910A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Refiere a un compuesto de formula (I), o un estereoisomero, o un atropisomero, o una sal farmaceuticamente aceptable del mismo o de un atropisomero, en donde, A se selecciona de un anillo heteroarilo de 8-10 miembros que comprende N, O, S o un anillo heterobiciclico parcialmente saturado de 8-10 miembros seleccionados de N, O, S y S(=O)2., entre otros; B se selecciona de B1, que es arilo C6-10 opcionalmente sustituido con 1, 2, 3 o 4 RBa, y de B2, que es un heteroarilo de 6-13 miembros con 1 - 3 atomos de nitrogeno y opcionalmente sustituido con 1, 2, 3 o 4 RBb; C se selecciona de -CH(CN)-CH3, -CH(OH)-CH3, entre otros; L se selecciona de un grupo que comprende RL, seleccionado de -CH2-CN, -CH2-OH, entre otros, y G , que representa el punto de union a G, en donde R2,R3,R4,R5,R6 Y R7 son hidrogeno, metilo, entre otros. Asimismo, se refiere a metodos para fabricar dicho compuesto y su uso para el tratamiento de un cancer o de un tumor solido, mediante una combinacion de agentes farmacologicamente activos y una composicion farmaceutica que comprende dicho compuesto.
PE2022001123A 2019-12-20 2020-12-17 Derivados de pirazolilo utiles como agentes anticancerigenos PE20221910A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951400P 2019-12-20 2019-12-20
PCT/CN2020/125425 WO2021120890A1 (en) 2019-12-20 2020-10-30 Pyrazolyl derivatives useful as anti-cancer agents
PCT/IB2020/062144 WO2021124222A1 (en) 2019-12-20 2020-12-17 Pyrazolyl derivatives useful as anti-cancer agents

Publications (1)

Publication Number Publication Date
PE20221910A1 true PE20221910A1 (es) 2022-12-23

Family

ID=76477081

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001123A PE20221910A1 (es) 2019-12-20 2020-12-17 Derivados de pirazolilo utiles como agentes anticancerigenos

Country Status (24)

Country Link
US (1) US11702409B2 (es)
EP (2) EP4344702A3 (es)
JP (2) JP2023506841A (es)
KR (1) KR20220114064A (es)
CN (1) CN114929342A (es)
AR (1) AR120855A1 (es)
AU (1) AU2020410531B2 (es)
CA (1) CA3165148A1 (es)
CL (1) CL2022001625A1 (es)
CO (1) CO2022008344A2 (es)
CR (1) CR20220281A (es)
DK (1) DK4076662T3 (es)
DO (1) DOP2022000124A (es)
EC (1) ECSP22047876A (es)
FI (1) FI4076662T3 (es)
IL (1) IL293893A (es)
JO (1) JOP20220155A1 (es)
LT (1) LT4076662T (es)
MX (1) MX2022007350A (es)
PE (1) PE20221910A1 (es)
PT (1) PT4076662T (es)
TW (1) TW202136241A (es)
UY (1) UY38990A (es)
WO (2) WO2021120890A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4051678A1 (en) 2019-10-28 2022-09-07 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
KR20230019462A (ko) 2020-06-02 2023-02-08 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
EP4214209A1 (en) 2020-09-15 2023-07-26 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
JP2023547194A (ja) * 2020-10-30 2023-11-09 ノバルティス アーゲー Ｋｒａｓ ｇ１２ｃ阻害剤化合物の新たな結晶形態
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022133731A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
MX2023007399A (es) * 2020-12-22 2023-07-06 Novartis Ag Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y usos de un inhibidor de kras g12c para el tratamiento de cancer.
CN117616031A (zh) 2021-05-05 2024-02-27 锐新医药公司 用于治疗癌症的ras抑制剂
EP4334321A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors
EP4340883A1 (en) * 2021-05-19 2024-03-27 Genentech, Inc. Combination therapy
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
WO2022269508A1 (en) * 2021-06-23 2022-12-29 Novartis Ag Pyrazolyl derivatives as inhibitors of the kras mutant protein
WO2023008462A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20230203062A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
TW202332429A (zh) 2021-11-24 2023-08-16 美商建南德克公司 治療性化合物及其使用方法
WO2023099592A1 (en) * 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023122662A1 (en) 2021-12-22 2023-06-29 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
WO2023143605A1 (en) * 2022-01-31 2023-08-03 Novartis Ag Process for the synthesis of pyrazolyl derivatives useful as anti-cancer agents
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023199180A1 (en) 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024040131A1 (en) 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
WO2024102421A2 (en) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
CN116478141B (zh) * 2023-06-20 2023-10-24 药康众拓(江苏)医药科技有限公司 氘代kras抑制剂药物及用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1199600A (en) * 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
AU2005280167A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as TGF-beta inhibitors
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CA2613522A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
EP2024353A2 (en) * 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
US7897619B2 (en) * 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
KR20100038119A (ko) * 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
WO2010108268A1 (en) * 2009-03-23 2010-09-30 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US9114137B2 (en) * 2010-08-03 2015-08-25 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
JP6399660B2 (ja) 2012-04-10 2018-10-03 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 癌治療用組成物および方法
TW201524952A (zh) 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
UA119971C2 (uk) 2013-10-10 2019-09-10 Араксіс Фарма Ллк Інгібітори g12c kras
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
AU2017266911B2 (en) 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CA3043383A1 (en) * 2016-11-14 2018-05-17 Jiangsu Hengrui Medicine Co., Ltd. 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof
CN108069955B (zh) * 2016-11-14 2021-04-06 江苏恒瑞医药股份有限公司 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用
JOP20190154B1 (ar) 2016-12-22 2022-09-15 Amgen Inc بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم
US20200385364A1 (en) 2017-01-26 2020-12-10 Araxes Pharma Llc Fused n-heterocyclic compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
EA202091186A1 (ru) * 2017-11-15 2020-10-01 Мирати Терапьютикс, Инк. ИНГИБИТОРЫ KRas G12C
WO2019136147A1 (en) * 2018-01-03 2019-07-11 The Board Of Trustees Of The University Of Illinois Toll-like receptor signaling inhibitors
MA51908A (fr) * 2018-02-23 2021-06-02 Samumed Llc Indazole-3-carboxamides substitués par hétéroaryle en position 5, préparation et utilisation associées
MA52501A (fr) * 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MX2020011907A (es) 2018-05-10 2021-01-29 Amgen Inc Inhibidores de kras g12c para el tratamiento de cancer.
CA3098885A1 (en) * 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same

Also Published As

Publication number Publication date
JP2024056707A (ja) 2024-04-23
JP2023506841A (ja) 2023-02-20
ECSP22047876A (es) 2022-07-29
KR20220114064A (ko) 2022-08-17
CO2022008344A2 (es) 2022-06-30
EP4344702A3 (en) 2024-04-10
PT4076662T (pt) 2024-04-18
US11702409B2 (en) 2023-07-18
AU2020410531B2 (en) 2024-03-07
EP4076662B1 (en) 2024-01-31
EP4344702A2 (en) 2024-04-03
WO2021120890A1 (en) 2021-06-24
IL293893A (en) 2022-08-01
CN114929342A (zh) 2022-08-19
AR120855A1 (es) 2022-03-23
CL2022001625A1 (es) 2023-03-24
LT4076662T (lt) 2024-05-10
DOP2022000124A (es) 2022-07-31
CR20220281A (es) 2022-07-01
CA3165148A1 (en) 2021-06-24
JOP20220155A1 (ar) 2023-01-30
WO2021124222A1 (en) 2021-06-24
EP4076662A1 (en) 2022-10-26
FI4076662T3 (fi) 2024-04-24
UY38990A (es) 2021-07-30
AU2020410531A1 (en) 2022-07-28
TW202136241A (zh) 2021-10-01
US20220363670A1 (en) 2022-11-17
MX2022007350A (es) 2022-07-19
DK4076662T3 (da) 2024-04-22

Similar Documents

Publication Publication Date Title
PE20221910A1 (es) Derivados de pirazolilo utiles como agentes anticancerigenos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
MX2022008066A (es) Compuestos triciclicos sustituidos.
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
ES2564179T3 (es) Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales
AR074876A1 (es) Derivados de indol-pirimidina para tratar cancer
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
RU2012140961A (ru) ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CO2022002729A2 (es) Métodos de tratamiento del cáncer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrógenos
ECSP045073A (es) Nuevos derivados de piperazina
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
AR058800A1 (es) Heterociclos condensados con anillos bencenicos como inhibidores de comt, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento del mal de parkinson
PE20212329A1 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
PE20200727A1 (es) Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso